吸入性皮质类固醇对COPD患者代谢功能障碍相关的脂肪性肝病风险的影响
相关实验视频
Updated: May 12, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Jiyu Sun1, Hyo Jin Lee2, Jung-Kyu Lee2
1Integrated Biostatistics Branch, Division of Cancer Data Science, National Cancer Center, Goyang-si, Republic of Korea.
在慢性阻塞性肺病 (COPD) 患者中长期使用吸入性皮质类固醇 (ICS) 可能会增加患有代谢功能障碍相关脂肪性肝病 (MASLD) 的风险. 需要进一步的研究,以找到减少这种风险的方法.
科学领域:
- 肺部病理学 肺部病理学
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在慢性阻塞性肺病 (COPD) 患者中,肝脏对长期吸入性皮质类固醇 (ICS) 的反应尚不清楚.
- 调查ICS治疗与COPD中代谢功能障碍相关的脂肪性肝病 (MASLD) 之间的潜在联系至关重要.
研究的目的:
- 为了确定长期的ICS治疗是否会增加COPD患者患MASLD的风险.
- 分析ICS使用和MASLD发病率在大型COPD队列中的关联.
主要方法:
- 一项回顾性队列研究利用来自大量人口数据库的索赔数据.
- 分析了40岁及以上没有以前慢性肝病史的COPD患者.
- 患者根据ICS的使用进行了分层,主要结果是MASLD的发展.
主要成果:
- 该研究包括442,880名COPD患者;95,695人使用ICS,347,185人没有.
- 在ICS组中,MASLD的发病率较高 (每10万人年859.3),而非ICS组 (410万人年440.4).
- ICS使用与增加MASLD风险 (HR=1.630) 有显著的关联,而Fluticasone furoate和更长的ICS持续时间显示出更高的风险.
结论:
- 在COPD患者中长期使用ICS可能与更高的MASLD风险有关.
- 需要进一步的研究,以制定减轻使用ICS的COPD患者中MASLD风险的策略.
- 这些发现突出了长期ICS治疗在COPD管理中的潜在不良肝脏效应.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:30Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
Published on: March 15, 2018
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation